Key result
Higher BMI in HF linked to increased risk of death or HF hospitalization.
Why the study?
Does genetically predicted higher BMI increase the risk of mortality and heart failure hospitalization in patients with established heart failure?
Observational (n=50,636)
Yes
Does genetically predicted higher BMI increase the risk of mortality and heart failure hospitalization in patients with established heart failure?
Hazard Ratio: 1.21 (95% CI 1.13–1.29)
p-value: p=9 × 10-8
Higher genetically predicted BMI is associated with increased all-cause mortality and cardiovascular death or HF hospitalization in patients with heart failure, regardless of ejection fraction.
Challenges HF obesity paradox across LVEF spectrum; leaves open whether weight loss improves outcomes.
BACKGROUND: Excess adiposity, most commonly indexed through body mass index (BMI), is strongly associated with the development of heart failure (HF). Weight loss therapies improve outcomes in patients with obesity and HF with preserved left ventricular ejection fraction (LVEF), but their effects in HF with reduced LVEF remain unclear. OBJECTIVES: The aim of this work is to determine whether higher BMI is associated with adverse clinical outcomes in patients with HF and whether there is effect modification by LVEF subgroup. METHODS: Two-sample Mendelian randomization (MR) was used, with genome-wide significant loci associated with BMI as instrumental variables and outcome data from a genome-wide association study (GWAS) of time-to-event clinical outcomes in patients with HF. A total of 50,636 individuals of European ancestry with established HF from 22 cohorts were included in the genetic analysis: 12 HF trials, 1 prospective case-cohort study, 9 cohorts nested within non-HF cardiovascular trials, and 1 population-based cohort derived from the UK Biobank. The exposure was genetically predicted BMI and the outcome measures were all-cause mortality and a composite of cardiovascular mortality or HF hospitalization. Genetic associations for the outcomes were derived from our GWAS and MR was used to estimate the unbiased association of genetically predicted BMI with these clinical outcomes. RESULTS: The mean BMI was 29.2 ± 5.8 kg/m2. Over a median follow-up of 27.0 months, all-cause mortality occurred in 11,454 patients (23%), and 11,360 participants (22%) experienced the composite endpoint. Genetically predicted BMI was associated with an increased rate of both all-cause mortality (HR per SD [4.8 BMI units] 1.21; 95% CI: 1.13-1.29; P = 9 × 10-8) and the composite outcome (HR 1.29; 95% CI: 1.20-1.38; P = 8 × 10-13). Associations were consistent across LVEF ≤40% and >40%: for all-cause mortality, HR: 1.16 (95% CI: 0.99-1.37) and 1.20 (95% CI: 0.94-1.53); and for the composite outcome, HR: 1.30 (95% CI: 1.15-1.48) and 1.57 (95% CI: 1.29-1.91), respectively. CONCLUSIONS: Among patients with HF, higher BMI was associated with increased all-cause mortality and cardiovascular death or HF hospitalization, supporting the potential role of weight-management strategies across the ejection fraction spectrum.
No takes yet. Share an insight, caveat, or question.
Sunderland et al. (2026) conducted an observational in Heart failure (n=50,636). Genetically predicted body mass index (BMI) was evaluated on All-cause mortality (HR 1.21, 95% CI 1.13-1.29, p=9 × 10-8). Genetically predicted higher BMI was associated with increased all-cause mortality (HR 1.21; 95% CI 1.13-1.29) and a composite of cardiovascular death or HF hospitalization (HR 1.29; 95% CI 1.20-1.38).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: